On June 30, Revolution Medicines rose 5.07% in regular trading, trading at $191.43/share, with turnover of $770 million.

On the news front, the company presented latest clinical data at the European Society for Medical Oncology Gastrointestinal Cancer (ESMO GI) annual meeting. Its second RAS inhibitor zoldonrasib combined with standard chemotherapy achieved an objective response rate (ORR) of 82% in first-line pancreatic cancer, while the chemotherapy-free doublet regimen of zoldonrasib plus daraxonrasib demonstrated a 50% ORR in the second-line setting, significantly exceeding market expectations.

UBS previously noted that positive doublet data could boost the company's pancreatic cancer revenue by 20% to 40%, and anticipated daraxonrasib would be approved and launched quickly. Additionally, Revolution Medicines has initiated patient treatment in its Rasolute 305 Phase 3 trial evaluating zoldonrasib plus chemotherapy as first-line therapy for RAS G12D metastatic pancreatic cancer, further expanding its frontline treatment portfolio.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)